Targeting a specific enzyme in brain cells to treat Alzheimer's disease
Microglial hexokinase 2 as a therapeutic target in Alzheimer's disease
This study is looking at how a specific enzyme in brain immune cells can be used to help treat Alzheimer's disease by understanding how these cells react to harmful plaques in the brain, with the hope of finding new ways to reduce inflammation and boost brain health for people with Alzheimer's.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10875709 on NIH RePORTER |
What this research studies
This research investigates how a particular enzyme, hexokinase 2, in brain immune cells called microglia, can be targeted to improve treatment for Alzheimer's disease. The study examines how these cells change their metabolism in response to amyloid plaques, which are characteristic of Alzheimer's. By understanding the metabolic shifts in microglia, researchers aim to find new therapeutic strategies that could help reduce inflammation and improve brain function in patients with Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those exhibiting early signs of cognitive decline.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or halt the progression of Alzheimer's disease.
How similar studies have performed: Other research has shown promising results in targeting metabolic pathways in immune cells for treating neurodegenerative diseases, suggesting potential success for this approach.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Landreth, Gary E. — Indiana University Indianapolis
- Study coordinator: Landreth, Gary E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.